Oral dolasetron mesylate in patients receiving moderately emetogenic platinum-containing chemotherapy

Cancer Journal from Scientific American

Volumn 3, Issue 1, 1997, Pages 45-51

  Grote, Thomas H ^a   Pineda, Luis F ^b   Figlin, Robert A ^c   Pendergrass, Kelly B ^d   Hesketh, Paul J ^e   Karlan, Beth Y ^f   Reeves, James A ^g   Porter, Lester L ^h   Benedict, Claude R ⁱ   Hahne, William F ^j  

^a Forsyth Hematology/Oncology   (United States)

^b Brookwood Oncology Associates   (United States)

^c UCLA MEDICAL CENTER   (United States)

^d Kansas City School of Medicine   (United States)

^e BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^f CEDARS SINAI MEDICAL CENTER   (United States)

^g Lee Coast Research Center   (United States)

^h St Thomas Medical Group   (United States)

ⁱ UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^j SANOFI   (France)

more..

Author keywords

Antiemetic; dose response; moderately emetogenic chemotherapy; oral dolasetron

Indexed keywords

CARBOPLATIN; CISPLATIN; DOLASETRON MESILATE;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; VOMITING;

ADMINISTRATION, ORAL; AGED; ANTIEMETICS; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CISPLATIN; DEMOGRAPHY; FEMALE; HUMANS; INDOLES; MALE; MIDDLE AGED; QUINOLIZINES; TREATMENT OUTCOME; VOMITING;

EID: 8244221657     PISSN: 10814442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Kris MG, Grunberg SM, Gralla RJ et al. Dose-ranging evaluation of the serotonin antagonist dolasetron mesylate in patients receiving high-dose cisplatin. J Clin Oncol 1994;12:1045-1049.
2. Boxenbaum H, Gillespie T, Heck K et al. Human dolasetron pharmacokinetics: I. Disposition following single-dose intravenous administration to normal male subjects. Biopharm Drug Dispos 1992;13:693-701.
3. 3 receptors. Drug Dev Res 1993;28:87-93.
4. Galvan M, Gittos MW, Fatmi M. Dolasetron mesylate. Drugs Future 1993;18:506-509.
5. Harman GS, Omura GA, Ryan K et al. A randomized, double-blind comparison of single dose and divided multiple-dose dolasetron for cisplatin-induced emesis. Cancer Chemother Pharmacol 1996;38:323-328.
6. 3 antagonist, in cancer patients treated with cisplatin. Am J Clin Oncol 1994;17: 97-102.
7. 3 receptor antagonist. Drug Dev Res 1995;34:289-296.
8. 3 antagonists MDL 73147EF (dolasetron mesylate) and MDL 74156 in NG108-15 neuroblastoma x glioma cells. Eur J Pharmacol 1992;219:9-13.
9. 3 receptor antagonist. Br J Pharmacol 1992;107(Suppl):449P.
10. Miller RC, Galvan M, Gittos MW et al. Pharmacological properties of dolasetron, a potent and selective antagonist at 5-HT3 receptors. Drug Dev Res 1993;28:87-93.
11. Hunt TL, Cramer M, Shah A et al. A double-blind, placebo-controlled, dose-ranging safety and pharmacokinetic evaluation of single-dose intravenous dolasetron mesylate in healthy male volunteers. J Clin Pharmacol 1995;35:705-712.
12. Heck K, Holmes GB, Adams MA et al. A double-blind, placebo-controlled, dose-rising tolerance study of intravenous MDL 73, 147EF in normal volunteers. Clin Pharmacol Ther 1992;51:186 (abstract PIII-62).
13. Hesketh PJ, Gundara DR, Hesketh AM et al. Dose-ranging evaluation of the antiemetic efficacy of intravenous dolasetron in patients receiving chemotherapy with doxorubicin or cyclophosphamide. Support Care Cancer 1996;4:141-146.
14. Gralla RJ. Current issues in the management of nausea and vomiting. Ann Oncol 1993;4(Suppl 3):3-7.
15. Hesketh P, Navari R, Grote T et al. Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. J Clin Oncol 1996;14:2242-2249.
16. Audhuy B, Cappelaere P, Martin M et al. A double-blind, randomised comparison of the antiemetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy. Eur J Cancer 1996;32: 807-813.
17. Chevallier B, Cappelaere P, Splinter T et al. IV dolasetron vs IV metoclopramide in emesis prevention after cisplatin chemotherapy. Support Care Cancer 1995;3:A16.
18. Hunt TL, Cramer M, Christy-Bittel J et al. Multiple-dose, placebo-controlled phase I study of oral dolasetron. Pharmacotherapy 1996;16:253-260.
19. Dixon RM, Cramer M, Shah AK et al. Single-dose, placebo-controlled phase I study of oral dolasetron. Pharmacotherapy 1996; 16:245-252.
20. Beck TM. Efficacy of ondansetron tablets in the management of chemotherapy-induced emesis: review of clinical trials. Sem Oncol 1992;19(Suppl 15):20-25.
21. Bleiberg HH, Spielmann M, Folkson G et al. Antiemetic treatment with oral granisetron in patients receiving moderately emetogenic chemotherapy: a dose-ranging study. Clin Therapeutics 1995;17:38-51.
22. Fauser AA, Duclos B, Chemaissani A et al. Therapeutic equivalence of single oral doses of dolasetron mesilate and multiple doses of ondansetron for the prevention of emesis after moderately emetogenic chemotherapy. Eur J Cancer 1996;32:1523-1529.
23. Tonato M, Roila F, Del Favero A. Are there differences among the serotonin antagonists? Supportive Care Cancer 1994;2:293-296.
24. Du Bois A, Meerpohl HG, Vach W et al. Course, patterns, and risk-factors for chemotherapy-induced emesis in cisplatin-pretreated patients: a study of ondansetron. Eur J Cancer 1992;28:450-457.
25. Sullivan JR, Leyden MJ, Bell R. Decreased cisplatin-induced nausea and vomiting with chronic alcohol ingestion. N Engl J Med 1983;309:796 (letter).
26. Gralla RJ, Tyson LB, Kris MG et al. The management of chemotherapy-induced nausea and vomiting. Med Clin North Amer 1987;71:289-301.
27. Shah AK, Bargava VO, Hahne WF et al. Population pharmacokinetics and pharmacodynamics of metabolite after intravenous administration of dolasetron mesylate in patients receiving cisplatin chemotherapy. Pharm Res 1995;12(Suppl):360 (abstract PPDM 8135).
28. Baltzer L, Kris MG, Hinkley L et al. Reversible electrocardiographic interval prolongations following the specific serotonin antagonists ondansetron (OND) and dolasetron mesylate (DM): a possible drug effect without sequelae? Proc Am Soc Clin Oncol 1994;13:A1489.
29. Lifsey DS, Gralla RJ, Clark RA et al. Electrocardiographic changes with serotonin antagonist antiemetics: rate of occurrence and clinical relevance. Proc Am Soc Clin Oncol 1993;12:A1611.
30. Rusthoven J, Pater J, Kaizer L et al. A randomized, double-blinded study comparing six doses of batanopride (BMY-25801) with methylprednisolone in patients receiving moderately emetogenic chemotherapy. Ann Oncol 1991;2:681-686.
31. Wantanabe H, Hasegawa A, Shinozaki T et al. Possible cardiac side effects of granisetron, an antiemetic agent, in patients with bone and soft-tissue sarcomas receiving cytotoxic chemotherapy. Cancer Chemother Pharmacol 1995;35:278-282.
32. 3 receptor antagonists, in anesthetized dogs. Drug Dev Res 1991;24:277-284.
33. Blackwell CP, Harding SM. The clinical pharmacology of ondansetron. Eur J Cancer Clin Oncol 1989;25(Suppl 1):21-24.
34. McDermott S, Songer S, Benedict C et al. Safety profile of dolasetron. Eur Hosp Pharm 1996;2(Suppl 1):25-31.